# Capecitabine Plus Toripalimab Maintenance Therapy in Metastatic Nasopharyngeal Carcinoma After First-line Treatment

> **NCT05484375** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Affiliated Cancer Hospital & Institute of Guangzhou Medical University** · enrollment: 40 (estimated)

## Conditions studied

- Metastatic Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** Capecitabine plus toripalimab

## Key facts

- **NCT ID:** NCT05484375
- **Lead sponsor:** Affiliated Cancer Hospital & Institute of Guangzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2022-09
- **Primary completion:** 2027-09
- **Final completion:** 2029-09
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2022-08-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05484375

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05484375, "Capecitabine Plus Toripalimab Maintenance Therapy in Metastatic Nasopharyngeal Carcinoma After First-line Treatment". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05484375. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*